|
 Conference Coverage
Highlights from the 12th World Conference on Lung Cancer - CME
Chandra Belani, MD, Penn State Cancer Center, Hershey, PA; David Spigel, MD, The Sarah Cannon Research Institute, Nashville, TN; David Jackman, MD, Dana-Farber Cancer Institute, Boston, MD. 12th World Conference on Lung Cancer: Updates in the Management of Early Stage Non-Small Cell Lung Cancer (NSCLC) - CME
Chandra Belani, MD, Penn State Cancer Center, Hershey, PA 12th World Conference on Lung Cancer: Advances in the Management of Advanced NSCLC: Are We Making Progress? - CME
David Spigel, MD, The Sarah Cannon Research Institute, Nashville, TN 12th World Conference on Lung Cancer: Malignant Pleural Mesothelioma Updates - CME
David Jackman, MD, Dana-Farber Cancer Institute, Boston, MA 12th World Conference on Lung Cancer: Advances in the Management of Small-Cell Lung Cancer (SCLC) - CME
David Spigel, MD, The Sarah Cannon Research Institute, Nashville, TN
Current Topics
Review of Fluorine-18-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography (FDG-PET) in the Follow-Up of Medullary and Anaplastic Thyroid Carcinomas
By Nasim Khan, MD, PhD; Noboru Oriuchi, MD, PhD; Tetsuya Higuchi, MD, PhD; Keigo Endo, MD, PhD. October 2005. Enhanced Detection of Hepatocellular Carcinoma
By Motawa E. El-Houseini, PhD, Mohammed S. Mohammed, PhD, Wael M. Elshemey, PhD, Tarek D. Hussein, PhD, Omar S. Desouky, PhD, and Anwar A. Elsayed, PhD. October 2005.
 Latest Lung Cancer News
Non-platinum Regimen Effective Palliation for Advanced NSCLC (12/5/2008)Researchers from Japan have reported that a regimen of Navelbine® (vinorelbine) plus Gemzar® (gemcitabine) followed by Taxotere® (docetaxel) is as effective as Paraplatin® (carboplatin) and Taxol® (paclitaxel) for initial treatment of patients with advanced non–small cell lung cancer (NSCLC). The details of this study appeared in the December 2008 issue of Lancet Oncology.
Gemzar® and Paraplatin® Equivalent to Platinol® and VePesid® for SCLC (12/4/2008)
Researchers from the United Kingdom have reported that a regimen of Gemzar® (gemcitabine) and Paraplatin® (carboplatin) is as effective palliation as standard Platinol® (cisplatin) and VePesid® (etoposide) for patients with poor-risk small cell lung cancer (SCLC) but with less toxicity. The details of this study appeared in an early online publication in Thorax on September 11, 2008.
Iressa® Improves Survival of EGFR-positive Lung Adenocarcinoma (12/3/2008)
Researchers from Japan have reported that Iressa® (gefitinib) improves survival in patients who have epidermal growth factor receptor (EGFR)-positive lung adenocarcinoma. The details of this study were reported in the December 1, 2008 issue of the Journal of Clinical Oncology.
Iressa® Equivalent to Taxotere® for Previously Treated NSCLC (12/2/2008)
Researchers affiliated with the international randomized trial, INTEREST, have reported that Iressa® (gefitinib) is non-inferior to Taxotere® (docetaxel) for salvage palliative treatment of patients with previously treated non–small cell lung cancer (NSCLC). The details of this study appeared in the November 22, 2008 issue of Lancet.
Pulmonary Scarring on Chest X-Ray Is Associated with Lung Cancer Incidence (12/1/2008)
Researchers affiliated with the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial have reported that pulmonary scarring is associated with the development of ipsilateral lung cancer. The details of this study were reported in the November 24, 2008 issue of the Archives of Internal Medicine.
More Lung Cancer News »
|
 Lung Cancer Drug Pipeline
What's in the pipeline for Lung Cancer.
Newsletters
Register in our member center today to receive a monthly newsletter with clinical
news, conference coverage, and current topic updates.
|
